PHVS Pharvaris NV

Pharvaris to Present at the GA²LEN UCARE Conference 2023

Pharvaris to Present at the GA²LEN UCARE Conference 2023

ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023, to be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

Presentation details:

  • Title: Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results

    Presenter: Markus Magerl, M.D.

    Date/Time: Friday, December 8, 11:18-11:26 a.m. BST (9:18-9:26 a.m. EST)

    Presentation Code: O07

    Type: Oral Presentation



  • Title: Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S

    Presenter: Danny M. Cohn, M.D.

    Date/Time: Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST)

    Presentation Code: P080

    Type: Happy Poster Hour Presentation



  • Title: Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant

    Presenter: Marcus Maurer, M.D.

    Date/Time: Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST)

    Presentation Code: P081

    Type: Happy Poster Hour Presentation

Pharvaris is a bronze level sponsor of the GA²LEN UCARE Conference 2023. Following the close of the respective sessions, the presentation slides and posters will be made available on the Investors section of the Pharvaris website at: .

About Pharvaris

Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit .



Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
EN
30/11/2023

Underlying

PHVSPharvaris NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharvaris NV

 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris Presents Data Highlighting the Potential for Deucrictibant t...

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Cli...

June 16, 2025 1 EN
 PRESS RELEASE
Free
PHVS PHARVARIS NV

Pharvaris Announces Annual Meeting of Shareholders

Pharvaris Announces Annual Meeting of Shareholders ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual ...

June 10, 2025 1 EN
Wedbush Research
  • Wedbush Research
VRNT VERINT SYSTEMS INC.
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
GME GAMESTOP CORP. CLASS A
MDB MONGODB INC. CLASS A
PHVS PHARVARIS NV
CGEM CULLINAN ONCOLOGY INC
PL PLANET LABS PBC
TLX TELIX PHARMACEUTICALS LIMITED
06/05/25 June 5, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
PHVS PHARVARIS NV

Pharvaris R&D day outlines plans to expand deucrictibant opportunity

Yesterday, Pharvaris hosted an R&D call to discuss plans for deucrictibant (oral B2 receptor antagonist) beyond HAE type 1/2. The company believes that deucrictibant could offer good outcomes for patients with normal C1-INH HAE, and this subset of patients is included in the phase 3 programs for on-demand and prophylaxis. In addition, the company pointed to the potential of deucrictibant to address acquired angioedema (AAE), where no approved treatments exist and investigator results demonstrate...

06/05/25 June 5, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
06/05/25 June 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch